非布司他治疗终末期肾病非透析状态伴高尿酸血症患者的临床效果

Clinical effects of Febuxostat in treatment of non-dialysis patients with end-stage renal disease and hyperuricemia

目的:探究非布司他治疗终末期肾病非透析状态伴高尿酸血症(HUA)患者的临床效果。方法:选取40例终末期肾病非透析状态伴HUA患者为研究对象,按照随机数字表法分为观察组和对照组,每组20例。两组均予终末期肾病非透析处理的常规治疗,观察组予非布司他治疗,对照组予别嘌醇治疗,比较两组临床疗效,治疗前后血尿酸(SUA)、血肌酐(Scr)及血尿素氮(BUN)水平,以及不良反应发生率。结果:观察组治疗总有效率为95.00%,高于对照组的55.00%,差异有统计学意义(P<0.05);治疗后观察组SUA、Scr、BUN水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:终末期肾病非透析状态伴HUA患者予非布司他治疗效果较好,可有效降低SUA水平,有助于延缓肾损伤进程,且安全性较高。

Objective:To explore clinical effects of Febuxostat in treatment of non-dialysis patients with end-stage renal disease and hyperuricemia(HUA).Methods:40 non-dialysis patients with end-stage renal disease and HUA were selected as the research objects,and were divided into observation group and control group according to random number table method,20 cases in each group.Both groups were given nondialysis routine treatment for end-stage renal disease.Besides,the observation group was treated with Febuxostat,while the control group was treated with Allopurinol.Then,the clinical efficacy,the levels of blood uric acid(SUA),blood creatinine(Scr)and blood urea nitrogen(BUN)before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate in the observation group was 95.00%,which was higher than 55.00%in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of SUA,Scr,and BUN in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Febuxostat is effective in the treatment of the non-dialysis patients with end-stage renal disease and HUA.It can effectively reduce the level of SUA and help to delay the progress of kidney injury with higher safety.